2. Cancer
  3. Cancer Metabolism and Metastasis

Cancer Metabolism and Metastasis

Metabolic abnormalities are a major feature of cancer, such as increased substance anabolic pathways and aerobic glycolysis. Cancer metabolism shows flexibility and plasticity, which are crucial for the survival and growth of cancer cells. Cancer metastasis is completed in five steps i.e. invasion, dissemination, circulating tumor cells, colonization, and secondary tumor formation. Recently, metabolic adaptation mechanism of cancer metastasis has been proposed to reveal the extensive relationship between cancer metabolism and cancer metastasis. Metastasizing cancer cells selectively and dynamically adapt their metabolism during the complex multistep cascade.

Many nutrients can promote metabolite plasticity during metastasis. For example, lactic acid and pyruvate are the nutrients that cells can directly absorb from the environment; many cancer cells take up glutamine, which contributes to non-essential amino acid as well as nucleotide synthesis through nitrogen or carbon metabolism. Inhibiting the function of key enzymes in metabolic pathways can in turn inhibit the proliferation of cancer cells. For example, lactate dehydrogenase A or B (LDH-A or -B) knockdown can inhibit breast cancer cell motility in vitro. Oncogenic signaling pathways, such as Myc, phosphoinositide 3-kinase (PI3K)/AKT pathway, MAPK/ERK pathway, LKB1/AMPK pathway and Hippo pathways, mediate metabolic gene expression and increase metabolic enzyme activities.

Cancer Metabolism and Metastasis 관련 제품 (50765):

Cat. No. 상품명 CAS No. Purity 화학구조
  • HY-W874392
    Tubulin polymerization-IN-74 54491-43-9 98.79%
    Tubulin polymerization-IN-74 (compound 11) is a Tubulin polymerization inhibitor, with IC50 of 15 μM. Tubulin polymerization-IN-74 can be used in anticancer research.
    Tubulin polymerization-IN-74
  • HY-161848
    TCP-MP-CA
    TCP-MP-CA (compound 11a) is an inhibitor of LSD1 demethylation enzymatic via binding to LSD1/CoREST complex. TCP-MP-CA exhibits an inhibitory effect on osteoclastogenesis, with an IC50 value of 0.14 µM.
    TCP-MP-CA
  • HY-169476
    Pyrrolidine linoleamide 3140-51-0
    Pyrrolidine linoleamide is a derivative of linoleic acid amide with anticancer activity. Pyrrolidine linoleamide exhibits antiproliferative activity against a range of cancer cell lines, with IC50 values of 12.0, 27.5, 7.7, 21.9, 36.6, 32.6, and 33.9 μg/mL against U251, MCF-7, NCI-ADR/RES, 786-0, NCI-H460, PC-3, and OVCAR-3 cell lines, respectively.
    Pyrrolidine linoleamide
  • HY-100578R
    AGK2 (Standard) 304896-28-4
    AGK2 (Standard) is the analytical standard of AGK2 (HY-100578). This product is intended for research and analytical applications. AGK2 is a selective SIRT2 inhibitor with an IC50 of 3.5 μM. AGK2 inhibits SIRT1 and SIRT3 with IC50s of 30 and 91 μM, respectively.
    AGK2 (Standard)
  • HY-N0510R
    Aristolochic acid A (Standard) 313-67-7
    Aristolochic acid A (Standard) is the analytical standard of Aristolochic acid A. This product is intended for research and analytical applications. Aristolochic acid A (Aristolochic acid I; TR 1736) is the main component of plant extract Aristolochic acids, which are found in various herbal plants of genus Aristolochia and Asarum. Aristolochic acid A significantly reduces both activator protein 1 (AP-1) and NF-κB activities. Aristolochic acid A reduces BLCAP gene expression in human cell lines.
    Aristolochic acid A (Standard)
  • HY-14664R
    Fluvastatin (Standard) 93957-54-1
    Fluvastatin (Standard) is the analytical standard of Fluvastatin. This product is intended for research and analytical applications. Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.
    Fluvastatin (Standard)
  • HY-100509R
    NPS-1034 (Standard) 1221713-92-3
    NPS-1034 (Standard) is the analytical standard of NPS-1034 (HY-100509). This product is intended for research and analytical applications. NPS-1034 is a dual inhibitor of AXL and MET with IC50s of 10.3 and 48 nM, respectively.
    NPS-1034 (Standard)
  • HY-103663R
    MAK683 (Standard) 1951408-58-4
    MAK683 (Standard) is the analytical standard of MAK683 (HY-103663). This product is intended for research and analytical applications. MAK683 is an embryonic ectoderm development (EED) inhibitor extracted from patent US20160176882 A1, compound example 2. MAK683 exhibits IC50s of 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay.
    MAK683 (Standard)
  • HY-46005
    Taltobulin intermediate-11 1822561-77-2
    Taltobulin intermediate-11 is an intermediate in the synthesis of Taltobulin (HY-15584). Taltobulin is a common toxin component in ADC preparation (ADC Cytotoxin), and it is also a powerful tubulin (Microtubule/Tubulin) inhibitor. Taltobulin disrupts tubulin polymerization, induces mitotic arrest, and induces apoptosis.
    Taltobulin intermediate-11
  • HY-180210
    Ghrelin receptor full agonist-3 2243167-93-1
    Ghrelin receptor full agonist-3 (Compound 22) is a selective, potent and orally active ghrelin receptor full agonist with an EC50 of 1.8 nM. Ghrelin receptor full agonist-3 can stimulate pulsatile secretion of growth hormone (GH), significantly increasing the frequency and duration of GH secretion, thereby inducing a sustained increase in insulin-like growth factor-1 (IGF-1) levels. Ghrelin receptor full agonist-3 can be used for the researches of cancer and chronic obstructive pulmonary disease.
    Ghrelin receptor full agonist-3
  • HY-172457
    NUCC-0200808
    NUCC-0200808 (Compound 12g) is an inhibitor of MNK1 with an IC50 of 42 nM. NUCC-0200808 reduces eIF4E phosphorylation and cell viability in AML cells, and induces apoptosis. NUCC-0200808 holds promise for research in the field of leukemia.
    NUCC-0200808
  • HY-100848R
    TX1-85-1 (Standard) 1603845-32-4
    TX1-85-1 (Standard) is the analytical standard of TX1-85-1 (HY-100848). This product is intended for research and analytical applications. TX1-85-1 is an irreversible Her3 (ErbB3) inhibitor with an IC50 of 23 nM. TX1-85-1 is also the first selective Her3 ligand, which forms a covalent bond with Cys721 located in the ATP-binding site of Her3. TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling.
    TX1-85-1 (Standard)
  • HY-174535
    Human TGFA mRNA
    Human TGFA mRNA encodes the human transforming growth factor alpha (TGFA) protein. TGFA is a ligand for the epidermal growth factor receptor, which activates a signaling pathway for cell proliferation, differentiation and development.
    Human TGFA mRNA
  • HY-116532
    YCW-E11 1519043-97-0
    YCW-E11 is a Bcl-2, and Mcl-1 inhibitor with Ki values of 0.83 and 0.33 μM, respectively. YCW-E11 induces cell apoptosis through the mitochondrial pathway and exhibits antitumor activity. YCW-E11 can be utilized in cancer research.
    YCW-E11
  • HY-10249R
    GSK-690693 (Standard) 937174-76-0
    GSK-690693 (Standard) is the analytical standard of GSK-690693 (HY-10249). This product is intended for research and analytical applications. GSK-690693 is an ATP-competitive pan-Akt inhibitor with IC50s of 2 nM, 13 nM, 9 nM for Akt1, Akt2 and Akt3, respectively. GSK-690693 is also an AMPK inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation.
    GSK-690693 (Standard)
  • HY-W052289R
    Methyl 6-bromo-1H-indole-3-carboxylate (Standard) 868656-97-7
    Methyl 6-bromo-1H-indole-3-carboxylate (Standard) is the analytical standard of Methyl 6-bromo-1H-indole-3-carboxylate (HY-W052289). This product is intended for research and analytical applications. Methyl 6-bromo-1H-indole-3-carboxylate is a marine-derived natural product with antitumor activity. Methyl 6-bromo-1H-indole-3-carboxylate showed growth inhibition against Staphylococcus epidermidis, exhibiting weak or moderate minimum inhibitory concentrations (MICs).
    Methyl 6-bromo-1H-indole-3-carboxylate (Standard)
  • HY-R04635A
    mmu-miR-139-3p Agomir
    mmu-miR-139-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    mmu-miR-139-3p Agomir
  • HY-110038
    FTI-277 TFA 1217447-06-7
    FTI-277 TFA is a farnesyltransferase (FTase) inhibitor. FTI-277 TFA inhibits Ras farnesylation, blocks the phosphorylation of downstream ERK1/2 and mTOR, and reduces membrane-bound active N-ras protein. FTI-277 TFA activates caspase 3, upregulates Bim expression, induces cell apoptosis, suppresses regulatory T cell expansion, enhances macrophage phagocytosis, and improves bacterial clearance. FTI-277 TFA activates the PI3K/Akt signaling pathway, inhibits osteoblast differentiation, and reduces the proliferation ability of neuroblastoma cells. FTI-277 TFA can be used in research related to head and neck squamous cell carcinoma, neuroblastoma, sepsis, and vascular calcification.
    FTI-277 TFA
  • HY-W700241
    Norharman-d7 1216503-21-7
    Norharman-d7 is deuterium labeled Norharmane. Norharmane (Norharman), a β-carboline alkaloid, is a potent and reversible monoamine oxidase inhibitor, with IC50 values of 6.5 and 4.7 μM for MAO-A and MAO-B, respectively. Norharmane causes antidepressant responses. Norharmane is also a prospective anti-cancer photosensitizer. Norharmane alters polar auxin transport (PAT) by inhibiting PIN2, PIN3 and PIN7 transport proteins, thus causing a significant inhibitory effect on the growth of Arabidopsis thaliana seedlings.
    Norharman-d<sub>7</sub>
  • HY-13735E
    Quinacrine methanesulfonate 316-05-2
    Quinacrine (Mepacrine) methanesulfonate is a potent, orally active antimalarial agent with antitumor effects in vitro and in vivo. Quinacrine dihydrochloride inhibits NF-κB and activates p53 signaling, inducing apoptosis in tumor cells.
    Quinacrine methanesulfonate